Associated Papers
Impact of CYP1A, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and NFIB genotypes on clozapine serum concentration in smokers and nonsmokers.
Lenk HÇ et al.
Therapeutic Advances in Psychopharmacology, 2025
Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics.
Brunet M et al.
Pharmaceutics, 2022
Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.
Demurtas S et al.
The Pharmacogenomics Journal, 2021
Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer.
Helland T et al.
Journal of Personalized Medicine, 2021
Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients.
Hannachi I et al.
The Pharmacogenomics Journal, 2021
Effects of Vitamin D Receptor, Cytochrome P450 3A, and Cytochrome P450 Oxidoreductase Genetic Polymorphisms on the Pharmacokinetics of Remimazolam in Healthy Chinese Volunteers.
Hu K et al.
Clinical Pharmacology in Drug Development, 2021
Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients.
Contreras-Castillo S et al.
Frontiers in Pharmacology, 2021
Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients.
Largeau B et al.
Progress in Transplantation (aliso Viejo, Calif.), 2019
Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
Soeria-Atmadja S et al.
Plos One, 2017
CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM et al.
Clinical Transplantation, 2016
Association of CYP3A variants with kidney transplant outcomes.
Traynor C et al.
Renal Failure, 2015
The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.
de Jonge H et al.
The Pharmacogenomics Journal, 2015
OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
Teft WA et al.
British Journal of Cancer, 2015
Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients.
Sharaki O et al.
Molecular Biology Reports, 2015
Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients.
Li CJ et al.
Plos One, 2014
Severe acute nephrotoxicity in a kidney transplant patient despite low tacrolimus levels: a possible interaction between donor and recipient genetic polymorphisms.
Quaglia M et al.
Journal of Clinical Pharmacy and Therapeutics, 2013
CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients.
Santoro AB et al.
Clinical Pharmacology and Therapeutics, 2013
Response to "CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients".
de Jonge H et al.
Clinical Pharmacology and Therapeutics, 2013
ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.
García M et al.
European Journal of Clinical Pharmacology, 2013
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Elens L et al.
Pharmacogenomics, 2013
CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes.
Okubo M et al.
The Journal of Toxicological Sciences, 2013
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Elens L et al.
Pharmacogenomics, 2011